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INTRODUCTION 
The new United States Acute Liver Failure Study Group (USALFSG) 
model to predict 21-day survival without liver transplantation (LT) in 
patients with acute liver failure (ALF) is based upon encephalopathy 
(HE) grade, vasopressor requirement, etiology Bilirubin and INR 
(figure 1). Derivation studies suggest good discrimination and high 
specificity in predicting transplant free survival. A threshold of <20% 
predicted survival has been suggested to identify LT candidates . 
The model has not been externally validated: in a large cohort of ALF 
patients we assessed its diagnostic performance and practical utility. 
RESULTS 
RESULTS 
PATIENTS AND METHODS 
 
• Study cohort drawn from 2 UK sites between 1998-2016 
• 1223 subjects.  
• 869 Favourable etiologies 
• 354 Unfavorable etiologies 
 
• 236 (19%) died without transplantation 
• 792 (65%) survived with medical management 
• 195 (16%) underwent transplantation 
• Hospital survival as primary outcome  
 
• Diagnostic test performance assessed using Area Under 
Receiver Operating Characteristics (AUROC) techniques and 
standard approaches with and without classification of 
transplanted patients as ‘non-survivors’. 
 
Table 1. Admission Clinical Features of Study Cohort. 
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External assessment of the USALFSG model to predict 
medical survival of ALF patients confirms: 
 
• Simplicity of use with readily available variables.  
 
• Good discrimination as assessed by AUROC.  
 
• Reasonable calibration. 
 
• Predicted survival threshold of <20% for identifying 
non-survivors had high specificity but low sensitivity, 
failing to identify half of non-survivors. 
 
• Model is unlikely to be sole tool to select LT 
candidates. 
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Figure 1. ALFSG Survival Prediction Model. 
 
Log Odds of Spontaneous survival =  2.67 - 0.95 (HE*) + 1.56 
(Etiology*) - 1.25(Vasopressor Use) – 0.70 (ln bilirubin) - 1.35 
(ln INR). 
Where: 
*HE:  
0= Grade 1 or 2  
1= Grade 3 or 4  
 
*Etiology:  
1= Favourable (Paracetamol/Pregnancy/Ischemia/HAV)  
0= Unfavourable (all others)  
 
Source: Clin Gastroenterol Hepatol  2016 Aug;14(8):1199-1206. 
 Variable   Died Transplanted Survived All 
            
Favourable (n)   160 75 634 869 
HE Grade >2 (n)   77 (48%) 31 (41%) 97 (15%) 205 (24%) 
INR   6.4 (3.9-9.7) 7.9 (6.4-10.8) 4.2 (2.7-6.1) 4.6 (3.0-7.2) 
Bilirubin (mg/dl)   4.3 (3.1-6.8) 4.2 (3.0-5.7) 4.5 (3.0-5.7) 4.4 (3.0-6.4) 
Vasopressors(n)   141 (88%) 56 (75%) 145 (23%) 342 (39%) 
            
Unfavourable (n)   76 120 158 354  
HE Grade >2 (n)   27 (36%) 33 (28%) 21 (13%) 81 (23%) 
INR   3.8 (2.3-7.8) 3.6 (2.7-5.3) 2.2 (1.5-3.8) 3.0 (2.0-4.9) 
Bilirubin (mg/dl)   15.8 (7.4-24.2) 22.7 (12.3-26.7) 9.5 (3.8-22.1) 15.9 (6.4-24.8) 
Vasopressors (n)   46 (60%) 37 (31%) 22 (14%) 105 (30%) 
    Died Transplanted Survived All 
            
Favourable (n)   160 75 634 869 
Predicted Survival   28% (17-49) 28% (18-41) 73% (54-84) 64% (34-81) 
            
Un favourable (n)   76 120 158 354  
Predicted Survival   11 (4-22) 17% (7-29) 46 (26-57) 25% ((9-48%) 
            
All   236 195  792  1223 
Predicted Survival   22% (12-41) 22% (10-34) 68% (45-82) 52% (24-76) 
a. All Etiologies: Including Transplants as ‘Non-survivors’ 
 n=1223 AUROC 0.858 (95%CI 0.837-0.877) 
b. All Etiologies: Excluding Transplants’ 
 n=1028 AUROC 0.838 (95%CI 0.814-0.860) 
  Including Transplants Excluding Transplants 
  n AUROC 95% CI n AUROC 95% CI 
Etiology             
Favourable 869 0.852 0.825-0.880 794 0.838 0.804-0.872 
Un favourable 354 0.811 0.766-0.856 234 0.829 0.773-0.886 
All 1223 0.858 0.837-0.879 1028 0.838 0.810-0.866 
              
HE ≤2 Only 937 0.863 0.837-0.888 806 0.824  0.785-0.863 
HE >2 Only 286 0.759 0.703-0.816 222 0.726 0.660-0.792 
Predicted Survival (%) 
Predicted 
Survival 
Sensitivity 95% CI Specificity 95% CI +LR 95% CI -LR 95% CI 
≤ 10% 24.36 20.4 - 28.7 97.85 96.6 - 98.7 11.35 6.9 - 18.7 0.77 0.7 - 0.8 
≤ 20% 46.87 42.1 - 51.7 92.93 90.9 - 94.6 6.63 5.1 - 8.7 0.57 0.5 - 0.6 
≤ 30% 65.89 61.2 - 70.4 86.62 84.0 - 88.9 4.92 4.1 - 6.0 0.39 0.3 - 0.5 
≤ 40% 77.96 73.7 - 81.8 78.79 75.8 - 81.6 3.68 3.2 - 4.2 0.28 0.2 - 0.3 
≤ 50% 85.61 81.9 - 88.8 70.96 67.7 - 74.1 2.95 2.6 - 3.3 0.2 0.2 - 0.3 
≤ 60% 90.49 87.3 - 93.1 58.59 55.1 - 62.0 2.18 2.0 - 2.4 0.16 0.1 - 0.2 
≤ 70% 95.36 92.9 - 97.1 46.59 43.1 - 50.1 1.79 1.7 - 1.9 0.1 0.06 - 0.2 
≤ 80% 99.07 97.6 - 99.7 23.86 20.9 - 27.0 1.3 1.3 - 1.4 0.039 0.01 - 0.1 
Predicted Survival Non-Survivor Survivor 
≤ 20% 124 40 164 
> 20% 44 78 122 
168 118 286 
Specificity Sensitivity Accuracy 
92.9% (90.9-94.6) 46.9% (42-51.7) 76.7 (74.6-78.5) 
Specificity Sensitivity Accuracy 
66.1% (59.1-72.5) 73.8% (68.9-78.3) 70.6% (64.8-75.9) 
Table 2. Predicted Survival in Cohort by Etiology and Outcome. 
Figure 2. Area Under Receiver Operating Characteristic Curves for Predicted survival.    
Table 3. AUROC in Cohort by Etiology and Outcome. 
Note: Plot shows observed survival (blue 
bars) in ranges of predicted survival. Red bars 
show midpoint of each predicted survival 
range; concordance of red and blue bars 
reflects perfect agreement. 
 
n=1223. All etiologies, transplants included.  
 
  
Predicted Survival Non-Survivor Survivor 
≤ 20% 202 56 258 
> 20% 229 736 965 
431 792 1223 
Table 4. Diagnostic test performance of predicted survival thresholds.  
Note:. n=1223. All etiologies, transplants included.  
95%CI; 95% Confidence Interval, +LR; positive likelihood ratio, -LR; negative likelihood ratio.  
 
  
Table 5. Illustrative 2x2 Contingency Tables for 20% Predicted Survival Threshold.  
a. All cases n=1223. Transplants included as non-survivors. 
b. HE grade >2 cases only n=286. Transplants included as non-survivors. 
Figure 3.  Calibration of predictive model. 
Figure 4. Diagnostic test performance of predictive model. 
Note: Plot shows Sensitivity (blue line) and specificity (red line) for thresholds of predicted survival. Fainter lines 
show 95% confidence intervals. 
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